FIELD: food industry.
SUBSTANCE: invention relates to food and pharmaceutical industry. Infant food composition, containing protein, fats, carbohydrates, nucleotides, nucleosides and nonprotein negatively charged polygalacturonic acid taken at in certain amounts. Application of composition for production of composition for infant feeding. Application of nutrient composition to produce composition for treatment and/or prophylactics of inflammatory disease, diarrhea, eczema and/or atopic dermatitis of a baby.
EFFECT: nutrient composition efficiently imitates protective action of human milk, in particular, against allergies and infections.
9 cl, 4 ex
The present invention relates to nutritional compositions for feeding babies, containing fat, protein, carbohydrate, nucleotide component, and their application.
Breastfeeding optimally supports the development of the baby and protects against infections and allergies. However, not all babies can get human milk. Therefore, there remains a need in the composition for infants, which mimics the functions of human milk. In addition to the desired similarity of the compounds of formula for babies and human milk is also particularly desirable to mimic the protective effect of human milk, in particular protection against allergies and infections.
According to the invention the molecular structure and the proportion of the component nucleotides are important factors for the biological activity of the nucleotide components, in particular nucleotides. It has been found that the combination of nucleotide components with negatively charged non-protein components of the effects of biological activity nucleotide components in the compositions power can be significantly increased.
Therefore, the present invention provides a nutrient composition comprising a nucleotide component and non-protein negatively charged pianoby or glycoconjugates component with a molecular mass of from 200 to 20000 Dalt is n (hereafter called NCC).
The proposed nutrient composition is particularly effective in respect of:
● enhance the proliferation of immune cells, improving the development of T-limfozitah subpopulations and increase or antibody-based test response;
● stimulate the development of the immune system of newborns;
● stimulate the development of the nervous system of the newborn;
● stimulate the development of the newborn and recovery of the gastrointestinal tract after surgery or disease;
● modulation of the intestinal flora, stimulate the synthesis of polyunsaturated fatty acids with long chain;
● anti-infectious, antibacterial/antiviral effects.
Not wanting to limit himself by theory, the inventors believe that the improved activity is the result of improved performance and delivery of negatively charged nucleotide component of the epithelial cells through the interaction of the NCC and the nucleotide component, for example, through hydrogen and salt bridges. Biologically active molecular anionic charge nucleotides condensed and molecular charge distribution changes favorable.
Data nutrient composition can be further improved by combining the nucleotide component and NCC with divalent cations, preferably calcium and/or zinc. is ation will improve the convergence of the nucleotide component and NCC in a liquid medium (for example, in the intestinal tract) through formation of hydrogen bonds/salt bridges, thereby further increasing the effects of interaction between NCC and nucleotide components.
The present invention offers a nutritional composition comprising protein, fat and carbohydrate and nucleotide component selected from the group consisting of nucleic acids, derivatives of nucleic acids, nucleotides, nucleosidases, polynucleotides, nucleosides, ribose, desoxyribose and dinuklyeozidofosfatov (NpxN); and non-protein negatively charged pianoby or glycoconjugates component with a molecular mass of from 200 to 20,000 daltons.
The proposed composition comprises a nucleotide component selected from the group consisting of nucleic acids, derivatives of nucleic acids, nucleotides, nucleosidases, polynucleotides, nucleosides, ribose, desoxyribose and dinuklyeozidofosfatov (NpxN).
Nucleic acids are typically heterocyclic pyrimidine bases cytosine, thymine, uridine and derivatives, such pseudouridine, dihydrouridine, ribothymidine, 4-thiouridine, 3-methylcytidine, N-acetylcytidine, lysidine and purine bases adenine and guanosine and derivatives, such 1-methyladenosine, N6-isopentenyladenosine, inose is, N7-methylguanosine, N2-dimethylguanosine and viosinho. Nucleosides, such as N-glycosides, are glycoconjugates pyrimidine or purine. Preferred nucleotides are pastefire nucleosides, which are monomers or polymers in the form of oligo - or polynucleotides. For this application especially suitable sources of raw materials, such as hydrolysates of deoxyribonucleic acid and ribonucleic acid, t-RNA and ribosomes obtained from the milk of animals, animal and plant tissues, yeast, bifidobacteria and lactobacilli, and synthetic molecules (Biochemistry, Donald Voet and Judith G. Voet, John Wiley and Sons, Inc. NY, second edition, chapter 28, pp.849).
Preferably the composition contains at least one nucleotide, preferably at least two, more preferably at least three nucleotides selected from the group consisting of cytidine of monophosphate (CMP), gunasena of monophosphate (GMP), adenosine monophosphate (AMF), uridine of monophosphate (MFIs) and inosine monophosphate (IMP).
In a more preferred embodiment, the compositions contains ribose as the nucleotide component, preferably D-ribose. D(-)ribose is pentosin sugar, which can be purchased in the form of a crystalline product. Ribose is the main component of nucleic acid, pre is respectfully the composition contains from 0.01 wt.% up to 50 wt.% ribose on the weight of dry product, more preferably from 0.05 wt.% up to 10 wt.%, still preferably from 0.5 wt.% up to 10 wt.%.
The proposed composition preferably contains from 5 to 100 mg of nucleosides and/or from 5 to 100 mg of nucleoside per 100 grams dry weight of the composition, more preferably from 5 to 50 mg. Nucleotides and/or nucleosides additionally stimulate the immune system, acting synergistically with NCC in this composition.
Negatively charged component
The proposed composition contains a negatively charged non-protein pianoby and glycoconjugates component (NCC) with a molecular mass of from 200 to 20,000 daltons.
NCC is negatively charged in water at pH 7. The negative charge is preferably created carboxyl, phosphate and/or sulfate group, most preferably a carboxyl group. Preferably NCC has a MW of from 1000 to 10,000 daltons. The weight ratio of the nucleotide component/NCC in this nutritional composition is preferably from 100 to 0.1.
Preferably NCC selected from the group consisting of glycosphingolipids, acidic oligosaccharides and validirovannyj oligosaccharides. Preferably validirovannyj the oligosaccharide is sialyllactose and/or disialogangliosides (DS-LNT). Glycosphingolipids are usually compounds with a monosaccharide, related to ceramide is m
Preferably NCC contains ganglioside (glycosphingolipid). Gangliosides are usually very complex oligoribonucleotide that contain one group or more groups of sialic acid (N-acyl, in particular acetyl, derivatives of neuraminic acid, the abbreviation "NANA") in addition to glucose, galactose and galactosamine. For this application, in particular, buttermilk, egg yolk lecithin are sources of raw materials of gangliosides (Biochemistry, Donald Voet and Judith G. Voet, John Wiley and Sons, Inc. NY, second edition, chapter 23). Therefore, this composition preferably contains egg yolk lecithin and/or buttermilk.
In a particularly preferred embodiment, the composition contains ganglioside selected from the group consisting of GM3, GM1 and GD1.
In a preferred embodiment, the composition contains alphaglucosidase as NCC. Alphaglucosidase are sulfate esters of galactosylceramide and lactosylceramide (often called "sulfatide or sulfates of lipids") with sulfate groups linked at position 3 galactosyl group.
The proposed composition preferably includes acidic oligosaccharides with degree of polymerization (SP) from 2 to 100, preferably from 2 to 60. The term acid or acidic oligosaccharide refers to oligosaccharides containing, m is Nisha least one acid group selected from the group consisting of N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid group and phosphoric acid. Acidic oligosaccharide preferably contains elements of uronic acid (i.e. polymer uronic acid), more preferably the elements of the galacturonic acid. The composition preferably contains from 0.1 to 10 grams of acid oligosaccharides per 100 grams dry weight of the composition, more preferably from 1 to 6 grams per 100 grams dry weight.
Structure I: polymeric acid oligosaccharides
where R is preferably selected from the group consisting of hydrogen, hydroxyl or acid groups, preferably hydroxyl; and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid group and phosphoric acid, and the remaining R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen. Preferably one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carbonophobia, group, sulfuric acid group and phosphoric acid, and the remaining R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents a free or esterified carboxylic acid, and the remainder of R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen; and n is an integer and refers to the number of exonic elements (see also degree of polymerization below), which may be any exonym element. Accordingly, n is an integer in the range of 1-5000. Preferably exony(s) element(s) is(are) member(s) of uronic acid.
Most preferably R1, R2 and R3 are hydroxyl, R4 is hydrogen, R5 represents a carboxylic acid, n is any number from 1 to 250, preferably from 1 to 10, and exonym element is the galacturonic acid.
Definition, measurement and analysis preferred acidic oligosaccharides, which are used in this method, presented in an earlier patent application of the applicants related to acid oligosaccharides, i.e. WO 0/160378.
Preferably the acid oligosaccharide has one element, preferably two end item uronic acid, which can be free or esterified. Preferably, the end element and the uronic acid selected from the group consisting of a galacturonic acid, glucuronic acid, guluronic acid, iduronovoy acid, mannurone acid, Rybarikova acid and alternova acid. These elements can be free or esterified. In an even more preferred embodiment, the end exony element has a double bond, which is preferably situated between the C4 and C5 provisions limit hexoses element. Preferably one end exonic elements contains a double bond. End hexose (e.g., uronic acid) preferably has a structure corresponding to figure 2.
Figure 2: Preferred end hexana acid group
where R is preferably selected from the group consisting of hydrogen, hydroxyl, acid groups, preferably hydroxyl (see above); and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid group and phosphoric acid, and the remaining R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen. Preferably one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterify the new carboxylic acid, group, sulfuric acid group and phosphoric acid, and the remaining R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents a free or esterified carboxylic acid, and the remainder of R2, R3, R4 and R5 represent a hydroxyl and/or hydrogen; and n is an integer and refers to the number of exonic elements (see also degree of polymerization below), which may be any exonym element. Accordingly, n is an integer in the range of 1-100 that represents the number exonic elements, and these hexose elements preferably are elements of the uronic acids, even more preferably represent the elements of the galacturonic acid. The group of carboxylic acids of these elements can be free or partially esterified, and preferably are at least partially methylated.
Most preferably R2 and R3 are hydroxyl, R4 is hydrogen, and R5 represents a free or esterified carboxylic acid.
Acidic oligosaccharides used in this invention is preferably derived from pectin, pectate, alginate, chondroitin, hyaluronic acid, heparin, heparan, bacterial carbohydrates, sialogogues, Phuc is the Idan, focalisation or carrageenan, more preferably from pectin and/or alginate. Preferably use pectin, often biochemically depolimerizovannogo. It is most preferable to use pectin, depolimerizovannogo pectinases.
We offer nutritional composition preferably contains a divalent cation. Divalent cation increases the spatial proximity of the nucleotide component and NCC, optionally modifying the charge density and increasing biological activity. Preferably the composition contains at least one divalent cation selected from the group consisting of magnesium, calcium, iron, chromium, manganese, molybdenum, copper and zinc. Preferably the composition contains at least calcium and/or zinc.
It is preferable in this composition include zinc. Zinc increases the biological activity of nucleotides in combination with data from NCC, and is essential for growth and development, immune functions micronutrient food, especially for babies. Zinc deficiency weakens the immune function in General and resistance to infection. Therefore, this composition mainly contains zinc, preferably in quantities of from 2 to 100 mg of zinc per 100 grams dry weight of the composition, more preferably from 3 to 25 mg of the Inka 100 g dry weight of this composition. Weight of zinc calculated using zinc as an element.
In another preferred embodiment, the composition contains calcium for improved interaction between charges. Calcium is also important in the diet of infants, and, therefore, its mainly been included in this composition. Preferably the composition contains from 150 to 1000 mg of calcium in weight from the dry weight of the composition as a whole.
The proposed composition can preferably be used in the form of milk powder for infants. Milk formula to infants given preferably in liquid form. The term "child" includes subtracted from the breast children and toddlers who.
In the preferred embodiment, this invention relates to a nutritional composition, which provides macronutrients food in the diet of infants. Therefore, the composition preferably contains from 30 to 60 EN% lipid, between 5 and 15 EN% protein and 25 to 65 EN% carbohydrates. Preferably the composition contains from 43 to 53 EN% lipid, from 7 to 11 EN% protein and from 43 to 53 EN% carbohydrates (EN% is short for energy percentage and represents the caloric contribution of each component to the total caloric content of the composition). The term "protein, protein, or protein (protein) component in this context is the total soderzhaniemmasla, polypeptides, peptides and amino acids. The carbohydrates in this composition presents preferably greater part of the lactose, i.e. preferably at least 75 wt.% from the digestible carbohydrates are made up of lactose, preferably at least 90 wt.%.
The content of essential fatty acids
The proposed composition preferably contains at least 10 wt.% linoleic acid (LA) from all fatty acids, preferably 11 to 20 wt.%, more preferably 12-15 wt.%. The composition preferably contains at least 1 wt.% alpha-linolenic acid (ALA) from all fatty acids, preferably 1.5 to 4 wt.% ALA, more preferably 2 to 2.5 wt.%. To reduce the stress to the intestine, the weight ratio LC/ALA is preferably in the range of 2-10, preferably 5-7,5. This composition preferably comprises from 0.05 to 5 wt.% gamma-linolenic acid (GLA) of total fatty acids, preferably from 0.1 to 1 wt.%. Preferably the composition contains from 0.05 to 5 wt.% stereonova acid (JCC), preferably from 0.1 to 1 wt.%.
The content of polyunsaturated fatty acids with long-chain
The proposed composition preferably contains at least one polyunsaturated fatty acid with a long chain of 20 or 22 carbon atoms (THOSE) in Koli is este, exceeding 0.1 wt.% of the total number of fatty acids selected from the group consisting of docosahexaenoic acid (DHA), arachidonic acid (AA) and eicosapentaenoic acid (EPA). Preferably the composition comprises DHA in an amount exceeding 0.1 wt.% of the total number of fatty acids, and AK in excess of 0.1 wt.% of the total number of fatty acids.
Preferably, at least one of THOSE in this group are included in amounts of between 0.15 and 1 wt.% from the content of fatty acids in the composition. Preferably, at least two of THOSE are present in amounts of between 0.15 and 1 wt.% from the content of fatty acids in the composition. Preferably the composition contains AK and DHA, more preferably AK, DHA and EPA.
Contents AK preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, most preferably is between 0.1 and 0.6 wt.% from the content of fatty acids. In this composition EPA and/or DHA mainly add to balance the action AK, for example, to reduce the potential Pro-inflammatory effects of metabolites AK. Excess metabolites AK can cause inflammation. Therefore, this composition preferably contains AK, EPA and/or DHA, and the weight ratio AK/DHA preferably above 0.25 is preferably above 0.5, more preferably above 1. The ratio AK/DHA is preferably less than 25, preferably less than 10. The weight ratio AK/EPA preferably is in the range between 1 and 100, more preferably between 5 and 20. The weight ratio of EPA/DHA is preferably 1 or less, more preferably less than 0.5.
In a preferred embodiment, the content of THOSE does not exceed 3 wt.% of the total content of fatty acids, since it is desirable to simulate human milk as closely as possible. For the same reason, the composition preferably contains less than 1 gram of omega-3 THOSE 100 grams of fatty acids, more preferably the amount is between 0.1 and 0.75 grams per 100 grams of fatty acids. The content of omega-6 THOSE preferably does not exceed 2 grams per 100 grams of fatty acids and is preferably from 0.1 to 0.75 grams per 100 grams of fatty acids.
THOSE and other fatty acids can be obtained in the form of free fatty acids in the form of triglycerides, in the form of phospholipids or a mixture of one or more of the above. This composition mainly contains at least one of AK and DHA in phospholipid form, as they reduce the incidence of inflammatory bowel disease. The composition preferably contains from 0.1 to 5 mg AK in phospholipid per gram of fat in a whole and from 0.1 to 5 mg of DHA in the phospholipid per gram of fat in General. Preferably AK and/or DHA, at least partially present in the form of phosphatidylcholine (PC) and/or phosphatidylethanolamine (PV), for example, containing AA and/or DHA PV and/or PF.
The proposed composition preferably contains newsweaver.ie oligosaccharides with degree of polymerization (SP) from 2 to 100. Oligosaccharides are believed important to provide the appropriate environment in the gut for best play and charge density of the combination of the nucleotide component and NCC. Newsweaver.ie oligosaccharides reduce the pH environment of the intestine, improving the biological activity of nucleotides. Preferably the composition contains from 0.1 to 12 grams neoslavery oligosaccharides per 100 grams dry weight of the composition, preferably from 3 to 8 grams, more preferably from 5 to 7.5 grams. After the dissolution of the powder in the liquid and the feeding liquid formula baby newsweaver.ie oligosaccharides in this number provide the desired effect without causing discomfort in the gut. Suitable newsweaver.ie oligosaccharides don't split or only partially broken down in the intestine by the action of acids or digestive enzymes present in the upper gastrointestinal tract of man (small intestine and stomach), but can ferentiates intestinal floras of the th person. These oligosaccharides are preferably water-soluble (above the solubility of 1 gram of oligosaccharide per liter of water). The average SP of this oligosaccharide is preferably less than 40, more preferably below 20. Optimally, the composition contains from 2 to 12 grams of oligosaccharides with SP 2 to 60, preferably from SP 2 to 10 (i.e., the sum of the weights of these oligosaccharides with JV equal to 2, 3, 4, 5, 6, 7, 8, 9 and 10).
In accordance with another variant, at least one of the oligosaccharides of this composition selected from the group consisting of inulin, fructo-oligosaccharides, neoslavery dextrins, galactooligosaccharides (including transplantological), xylooligosaccharides, arabinopyranoside, glucooligosaccharides, mannooligosaccharides, lacto-N-neoteroi, focalisation (containing at least one falosny charigny element), acidic oligosaccharides (e.g., uronic acid oligosaccharides, such as pectic oligosaccharides and mixtures thereof.
Preferably the composition contains at least one selected from the group consisting of inuline and fructo-oligosaccharides, and at least one selected from the group consisting of galactooligosaccharides (including transplantological) and pectin hydrolysate. In a particularly preferred embodiment, the composition contains is it from 2 to 12 grams of oligosaccharides with SP from 2 to 10 and β-linked sugars, galactose and glucose, more preferably of transplantationfollow (i.e. [gal]n-glu, where n ranges from 2 to 10). In a particularly preferred embodiment, the composition contains transplantological (i.e. [gal]n-glu, where n ranges from 2 to 10), pectin hydrolysate and at least one selected from the group consisting of fructo-oligosaccharides and inulin. This oligosaccharide is preferably derived from milk of animals, a mixture of oligosaccharides derived from milk of animals or pulselearning oligosaccharide (oligosaccharide containing at least one falosny charigny element).
With regard to the further improvement of the development of the intestine over the entire area of the large intestine preferably at least 10 wt.% oligosaccharides in this composition had a JV from 2 to 5 (i.e. 2, 3, 4 and 5), and at least 5 wt.% had a JV from 10 to 100. Preferably, at least 50 wt.%, more preferably at least 75 wt.% oligosaccharides have SP 2 to 10 (i.e. 2, 3, 4, 5, 6, 7, 8, 9 and 10), as they are believed to act in the ileum and proximal and middle parts of the large intestine, and because the weight percent of the oligosaccharides, which must be included in the composition to achieve the desired action is reduced.
Preferably the weight ratio:
(oligosaccharides with JV 2-5): oligosaccharides with JV 6-9), and
(oligosaccharides with JV 10-100): (oligosaccharides with JV 6-9), both above 1. Preferably both weight ratio higher than 2, more preferably above 5.
The composition preferably contains from 0.5 to 10 grams of galactooligosaccharide JV between 2 and 10 per 100 grams dry weight of the composition, more preferably between 1 and 5 grams. The preferred galactooligosaccharide is transplantological because it best simulates human oligosaccharides. This invention preferably contains from 0.5 to 10 grams of fructooligosaccharide JV between 10 and 60 per 100 grams dry weight of the composition, more preferably between 1 and 5 grams. The term "fructooligosaccharide" refers to the polysaccharide carbohydrate consisting of a chain of at least 10 associated β-communication fructose elements.
We offer nutritional composition preferably is in the form of powder or liquid, or in the form of a tablet and this tablet has a weight of from 5 to 25 grams. Preferably this composition is presented in powder form, as this increases its shelf life. This composition is preferably used in oral liquid form. Before applying this composition it is preferably mixed with a liquid, preferably with water.
Violations of the chair (e.g. solid and is pregnene, insufficient volume of stool, diarrhea) are a major problem in many infants and patients who receive liquid products. It was found that the problems of the chair can be reduced by applying this composition in liquid form, having an osmolarity of between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg, most preferably between 220 and 300 mOsm/kg
In view of the above problems of diarrhea it is also important that the liquid food has no excessive concentration of calories, as it is a cause of significant stress to the intestine. However, it is necessary that the composition provides sufficient calories to feed the baby. Therefore, liquid food preferably has a specific caloric value between 0.5 and 0.9 kcal/ml, preferably between 0.6 and 0.8 kcal/ml
The proposed composition preferably give to babies aged between 0 and 2 years. This composition can also preferably be used in the method of providing nutritional support premature baby (baby born before 37 weeks of pregnancy). In a preferred embodiment, the invention provides a method of feeding infants from 0 up to 30 days.
The proposed composition can preferably be used for the treatment or prevention of diseases, and oslablen the I immune system and/or immaturity of the intestinal barrier underlies the development and course of disease. This composition, therefore, can preferably be used for the treatment or prevention of diarrhea or allergies, particularly in infants aged between 0 and 2 years. This composition is particularly suitable for the treatment and/or prevention of allergic rhinitis, allergic conjunctivitis, allergic dermatitis, atopic dermatitis and/or food allergies. In the preferred embodiment, this method is a method of treatment and/or prevention of infections, and this method includes the use of this composition.
The present invention is further illustrated by the following examples:
Example 1: Nutrition for young children
Liquid for feeding babies was prepared by mixing of 13.9 g of the powder with water to obtain 100 ml of the final product, with the specified liquid product contains 100 ml:
Energy: 66 kcal
Protein: 8 EN%
1.3 g (containing 0.6 g of casein, 0.8 g of whey 0,072 g of L-arginine);
Easily digestible carbohydrates: 44 EN%
of 7.4 g (containing 7,3 g lactose);
Fat: 48 EN%
3.5 g (content was 0.41 g of linoleic acid, 0.08 g of α-linolenic acid, 0,012 g arachidonic acid, 0.002 g eicosapentaenoic acid, 0,006 g docosahexanoic acid, 1.4 g of oleic acid);
0.8 g (containing 0.05 g fructooligosaccharide (Raftiline HP™, Orafti, Tienen, Belgium), 0.55 g of transplantological is s (Vivinal-GOS™; Borcolo Domo Ingredients, Netherlands), 0.20 g of hydrolyzed pectin, obtained as described in EP 1373543, example 1;
0,89 mg citizen-5-monophosphate,
0.55 mg of uridine-5-monophosphate,
0,82 mg adenosine-5-monophosphate,
0,20 mg guanosine-5-monophosphate,
0,34 mg inosine-5-monophosphate;
5 mg GM3, 50 mg obtained from pectin oligosaccharides with JV between 5 and 50 and 20 mg sialyllactose;
Calcium: 53 mg calcium;
Zinc: 0.8 mg zinc;
Osmolarity: 300 mosmol/L.
The composition additionally contains choline (6 mg/100 ml) and taurine (6,3 mg/100 ml); minerals and trace elements, and vitamins in amounts in accordance with international guidelines for the composition of infant formula for infants.
The composition of example 1, and the nucleotide component is replaced by dinucleotidephosphate (NpxN)Gp4G.
The composition of example 1, and the nucleotide component is an extract DNA/RNA oligomers.
The composition of example 1 containing 1 wt.% D-ribose from the dry weight of the composition as a whole.
Campsite baby food containing 5-15 EN.% protein, 30 to 60 EN.% fat and 25-65 EN.% carbohydrate and
a) from 5 to 50 mg of nucleotides and nucleosides on 100 g of dry weight of the composition, and
b) non-protein negatively charged polygalacturonase acid with a degree of polymerise the AI from 2 to 100 and a molecular weight from 200 to 20000 Da.
2. The composition according to claim 1, in which the protein is negatively charged polygalacturonase acid with degree of polymerization from 2 to 100, has a molecular weight of from 1,000 to 10,000 Da.
3. The composition according to claim 1 or 2, containing from 0.1 to 10 g polygalacturonic acid with degree of polymerization from 2 to 100 per 100 g dry weight of this composition.
4. The composition according to claim 1 or 2, containing from 150 to 1000 mg of calcium and/or from 2 to 100 mg of zinc each 100 g of dry weight of the composition.
5. The composition according to claim 1 or 2, in which polygalacturonase acid having a degree of polymerization of from 2 to 100, is hydrolyzed pectin.
6. The composition according to claim 1 or 2, in which polygalacturonase acid has a degree of polymerization of from 2 to 60.
7. The use of a composition according to any one of claims 1 to 6 to obtain a composition for feeding baby.
8. The use of the nutritional composition according to any one of claims 1 to 6 to obtain a composition for treatment and/or prevention of inflammatory diseases, diarrhea, eczema and/or atopic dermatitis in the infant.
9. The use of claim 8, in which the inflammatory disease is allergic.
SUBSTANCE: invention relates to novel compounds selected from a group comprising 2,3,4,9-tetrahydro-1H-carbazoles of formula I
where R1, R2, R3 and R4 independently denote hydrogen, alkyl, alkoxy, halogen, nitro, cyano, trifluoromethyl or formyl, R5 denotes hydrogen, alkyl or -CF3, R6 denotes alkoxy, arylalkoxy, selected from benzyloxy and 1-phenylethoxy, or -NR7R8, R7 and R8 independently denote hydrogen, alkyl, cyanoalkyl, alkenyl, where alkenyl is ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl or 5-hexenyl; aryl, where aryl is a phenyl or naphthyl radical, where said radicals can optionally be monosubstituted with a halogen, alkyl, alkoxy, -CF3, -OCF3, phenylalkyl or phenylcarbonyl; or disubstituted with a substitute independently selected from halogen, alkoxy and phenyl; arylalkyl, where arylalkyl is phenylalkyl, where the alkyl group can optionally be substituted with phenyl; phenylalkyl, where the phenyl ring can optionally be substituted with methylenedioxy; phenylalkyl which is disubstituted with a halogen; phenylalkyl which is monosubstituted with a halogen, -CF3, -OCHF2, alkyl or alkylsulfanyl; or naphthylalkyl; phenylcarbonyl; cycloalkyl, where cycloalkyl is a cyclopentyl or cyclohexyl radical, where said radicals can optionally be substituted with a condensed benzene ring; pyridylalkyl; thienylalkyl; or R7 and R8 together with a nitrogen atom to which they are bonded form a heterocyclic 5-, 6-, 7- or 8-member ring system containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur atoms, wherein said cyclic system can optionally be substituted with (1) one or two condensed benzene rings, where the benzene rings are unsubstituted or substituted with one or two substitutes independently selected from a group comprising C1-C4alkyl, C1-C4alkoxy, halogen, -CF3 and -OCF3; (2) unsubstituted phenyl ring, (3) mono- or disubstituted phenyl ring, where the substitutes are independently selected from a group comprising halogen, C1-C4alkyl, C1-C4alkoxy, -CF3 and -OCF3; or (4) phenylalkyl, where the alkyl group is substituted with phenyl; where the term "alkyl", separately or in any combination, denotes a saturated straight or branched hydrocarbon chain containing 1-7 carbon atoms; where the said alkyl group is unsubstituted unless stated otherwise; or to pharmaceutically acceptable salts thereof. Invention also relates to a pharmaceutical composition and to use of compounds in claim 1.
EFFECT: obtaining novel biologically active compounds having CRTH2 receptor antagonist activity.
13 cl, 5 tbl
SUBSTANCE: invention relates to medicine, namely to allergology, and can be applied for treatment of allergic rhinitis of domestic etiology. For this purpose in treatment included is allergen-specific immunotherapy with sublingual introduction of cause-significant allergen. Simultaneously hirudotherapy with application of medical leech on skin in region of oral cavity bottom projection is carried out. Procedures are carried out 2 times per week, starting from 0.1 ml 10-6 degree of dissolving of cause-significant allergen and bringing up to 0.5 ml of undissolved allergen, which after that is introduced 1 time per 2 weeks during 3 years.
EFFECT: invention allows to increase treatment efficiency due to increase of cause-significant allergen penetration into system of organs of mucosal immunity of upper airways.
SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for treating angioedemas. For this purpose introduced are antihistamine preparations, membrane-stabilisers, as well as pulmicort as glucocorticosteroid preparation. Pulmicort is introduced in amount 10 drops per 2 ml of physiological solution by inhalations through nebuliser during 3 minutes. Introduction of pulmicort is carried out daily during 1-3 days.
EFFECT: invention allows fast reduction of gullet and pharynx angioedemas due to direct impact on mucous membranes by said glucocorticosteroid in dose and mode of introduction specially designed for this purpose.
SUBSTANCE: invention refers to new compounds of formula I in the form of salt where J means a C1-C2 alkylene; R1 means cyclopentane, cyclohexyl, phenyl or thiophenes; R2 means hydroxy; R3 means a cyclopentane, cyclohexyl, phenyl or thiophenes; with R1 and R3 are not identical, or -CR1R2R3 together form a group of the formula , where Ra means a chemical bond, and Rb means hydroxy; R4 means methyl; R5 means C1 alkyl substituted with -CO-NH-R6; R6 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur; or J means C1-C2 alkylene; R1 and R3 both mean phenyl; R2 means hydroxy; R4 means methyl, R5 means C1 alkyl substituted with -CO-NH-R9; and R9 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur. The invention also refers to pharmaceutical composition, to application of compound according to any of clauses 1-3, as well as to method for obtaining a compound of formula I according to clause 1.
EFFECT: obtaining new biologically active compounds having antagonistic activity against muscarinic receptor M3.
7 cl, 21 ex
SUBSTANCE: novel 1,2,4-triazole derivatives - protein kinase inhibitors of formula (I) are described, where X - N; Y - CH2, NH, NR or 0; R1 and R2 each independently denote hydrogen; R3 is phenyl, substituted with -CN, 6-member heteroaryl containing 1-2 N atoms, possibly substituted with a 7-member heterocyclyl containing 2 nitrogen atoms, which in turn is substituted with C1-6alkylcarbonyl; R4 is hydrogen; R5 is hydrogen or -CN; and R is a C1-6alkyl group, C1-6alkylcarbonyl group substituted with -CN, or a C3-6cycloalkyl group, a method of inhibiting FLT-3 or c-KIT protein kinase.
EFFECT: obtaining novel compounds and their use in making a medicinal agent for treating or relieving acute myelogenic leucosis.
11 cl, 1 tbl, 13 ex
FIELD: medicine, veterinary science.
SUBSTANCE: agent for treating inflammatory and allergic skin disease in cats and dogs contains Polcortolon as a glucocorticosteroid, Levomycetin and Metronidazole as an antibiotic, excipients - lidocaine hydrochloride, dimethyl formamide, dimethyl sulphoxide, isopropyl alcohol and polyethylene glycol 400, additionally contains calendula extract and Metronidazole, in the following ratio, wt %: Polcortolon 0.01-3.0; Levomycetin 0.1-3.0; lidocaine hydrochloride 0.1-6.0; dimethyl formamide 10.0-15.0; dimethyl sulphoxide 10.0-15.0; calendula extract 0.1-4.0; Metronidazole 0.1-5.0; polyethylene glycol 400 10.0-15.0; isopropyl alcohol - the rest.
EFFECT: invention provides reduced recovery time of allergic and inflammatory functional condition of skin in an animal.
SUBSTANCE: benzamide derivatives are presented by the formula  or its salt, where Z is -O-, -NR5-, -S-, -SO-; 1 is 0 or 1; m is 0 or 1; R1 is hydrogen atom, C1-6-alkyl group, R2 is hydrogen atom, hydroxylic group, C1-6- alkyl group, carboxyl group, C1-6-alkoxycarbonyl group or -CONR10R11, or R2 and R1 together form =O; R3 is hydrogen atom or C1-6-alkyl group; R4 is hydrogen atom or halogen atom; V is direct bond or -(CR21R22)n-; P1 and P2 rings are the same or different, and each is aromatic or saturated carbocyclic group, or 5-10-member saturated or unsaturated heterocyclic group containing 1-3 heteroatoms selected out of N, O, S.
EFFECT: obtainment of compound with excellent inhibition effect on vanilloid receptor type 1 activity, efficiency in treatment of diseases involving vanilloid receptor type 1 activity.
17 cl, 56 tbl, 8 ex
SUBSTANCE: invention belongs to medicine, notably to hepatology, and relates to viral hepatitis A treatment in children with food allergy in acute phase of disease. On admission to hospital patient receives usual complex therapy of hepatitis, complemented with antihistaminic drugs - suprastin or tavegil, and enzymatic drugs - pancreatin or mesym - forte. Suprastin or tavegil is administered ј - 1 tablet after meal two times a day during 7-10 days. Pancreatin or mezym-forte is administered Ѕ-1 tablet 3 times a day during 14-18 days.
EFFECT: method fastens children recovery and reduces frequency of disease residual effects.
1 ex, 6 tbl, 4 dwg
SUBSTANCE: present invention relates to phenylalanine derivatives and their pharmaceutically acceptable salts. In formula (1) R11 is a hydroxyl group, an alkoxyl group having 1-6 carbon atoms, which can be substituted with a methoxy group, cycloalkoxyl group having 3-6 carbon atoms, or a benzyloxy group; R12 and R13 each independently represents a hydrogen atom, alkyl group having 1-6 carbon atoms, cycloalkyl group having 3-6 carbon atoms, acetyl group or methyloxycarbonyl group, or N(R12)R13 is a 1-pyrrolidinyl group, 1-piperidinyl group, 4-morpholinyl group; R14 is a methyl group; R1' is a hydrogen atom, fluorine atom; X1 is -CH(R1a)-, -CH(R1a)CH(R1b)-, -CH(R1a)CH(R1b)CH(R1c)-, -N(R1a)CH(R1b)CH(R1c)-, -OCH(R1a)CH(R1b)-, -OCH(R1a)CH(R1b)CH(R1c)- or 1,3-pyrrolidinylene, where R1a, R1b, each independently represents a hydrogen atom or a methyl group, and R1c is a hydrogen atom; Y11 and Y12 represent any of the combinations (CI, Cl), (CI, Me), (CI, F). Invention also relates to phenylalanine derivatives of formulae (2)-(14), given in the formula of invention.
EFFECT: obtaining a pharmaceutical composition having antagonistic effect on α4-integrin, containing a phenylalanine derivative as an active ingredient, a α4-integrin antagonist and a therapeutic agent.
65 cl, 51 tbl, 244 ex
SUBSTANCE: invention relates to a compound of formula (I) capable of bonding with S1P receptor (specifically EDG-6, preferably EDG-1 and EDG-6), its non-toxic water-insoluble salts or its methyl or ethyl ester.
EFFECT: obtaining compounds which can be used in preventing and/or treating graft rejection, graft-versus-host diseases, autoimmune diseases and allergic diseases.
11 cl, 66 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry. Vitamin E, ocimum basilicum oil, coconut oil, cloves oil, lemon oil and eucalyptus oil are mixed in the ratio, wt %: vitamin E 0.0001-0.001; ocimum basilicum oil 1.0-10.0; pine oil 1.0-20.0; coconut oil 1.0-15.0; cloves oil 1.0-10.0; lemon oil 1.0-10.0; eucalyptus oil - the rest, Cremophor is added to the prepared mixture in the ratio 1:(0.8-1.2) respectively. Then iron sulphate, alanine, tryptophan, isoleucine and water are mixed in the following ratio, wt %: iron sulphate 0.1-3.0; alanine 0.1-0.5; tryptophan 0.1-0.5; isoleucine 0.1-0.5; water - the rest. The mixed vitamin E, vegetable oils and Cremophor are combined connect in continual stirring at room temperature with the composition containing iron sulphate, alanine, tryptophan, isoleucine and water in the ratio 1:(1-500), respectively.
EFFECT: invention allows higher effectiveness of the composition.
3 cl, 13 ex, 2 tbl
SUBSTANCE: invention can be used as a wound healing agent in treatment of the infected, traumatic and burn skin damages. The wound healing probiotic contains wt %, related as follows: biomass of Bacillus subtilis 60T bacteria strain (RNCIM B-9907) and Lactobacterium plantarum bacteria 8P-A3 - 3÷5; silicon organic glycerohydrogel - 50÷60; glycerine - 20÷25; physiologic saline - the rest to 100.
EFFECT: invention provides higher wound healing activity of said agent for a shorter period of wound healing.
2 tbl, 2 ex
SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for patients with surgical sepsis. For this purpose subcutaneously introduced is sandostatin in dose 100 mkg 5 times per day and roncoleukin in dose 500 thousand IU 1 time per day. Introduction is realised for 2 days and 3 days after operation, as well as in 1 and 2 weeks of post operational period. Simultaneously on the same days during 1 hour hyperbaric oxygenation is carried out with partial pressure of oxygen 1.5-2 atmospheres.
EFFECT: method allows to reduce frequency of fatal outcomes in patients with said pathology due to immunomodelling action, which appears as a result of definite combination of pharmacological medications and hyperbaric oxygenation.
SUBSTANCE: present invention relates to novel compounds - 9-substituted derivatives of 8-oxoadenine of general formula (I) and their pharmaceutically acceptable salts having interferon-inducing effect on viruses. In general formula (I): , ring A is phenyl; n equals 0; Z1 is a C1-C4alkylene group which is not substituted or substituted with a hydroxyl group; X2 is an oxygen atom, a sulphur atom, SO2, NR5, SO2NR5, NR5SO2 or NHCONH (in which R5 is a hydrogen atom, a substituted or unsubstituted C1-C6alkyl group, where the substitutes are selected from a hydroxyl group, C1-C6-alkoxy group, amino, C1-C6-alkylamino, di- C1-C6-alkylamino, 5-6-member saturated cycloamine group containing 1-2 nitrogen atoms, possibly containing an extra oxygen atom and possibly substituted with an oxo-group, and a tetrazolyl group); Y1, Y2 and Y3 each independently denotes a single bond or a C1-C4-alkylene group; X is an oxygen atom; R2 is a hydrogen atom, a C1-C4-alkyl group optionally substituted with an amino group, a C1-C6-alkylamino group or a di- C1-C6-alkylamino group and R1 is a hydrogen atom.
EFFECT: obtaining novel compounds which can be used as an antiviral or antiallergic agent.
14 cl, 32 tbl, 51 ex
SUBSTANCE: invention relates to molecular pharmacology and specifically to a peptide which is part of an interleukine-15 (IL-15) sequence which can inhibit biological activity of the said molecule.
EFFECT: obtaining a peptide which inhibits T cell proliferation induced by IL-15, and apoptosis caused by tumour necrosis factor when bonding with the alpha subunit of the (IL-15R) receptor.
8 cl, 4 dwg, 5 ex
SUBSTANCE: invention refers to high-molecular compounds for medical purposes. Water-soluble polymeric complexes of antiviral agent arbidol of general formula: are described, where: Arb - arbidol: ethyl ester 6-bromo-4-dimethyl-aminometil-1-methyl-5-oxy-2-feniltiometilindolinil-3-carboxylic acid hydrochloride monohydrate; m1=100-(m2+m3) mol %; m2=(7.6-9.8) mol %; m3=(11.5-13.6) mol %; content of Arb=26.4-32.1 wt %.
EFFECT: obtained water-soluble polymeric complexes of arbidol may find application in pharmacology, as they can serve as basis for new effective and safe antiviral drugs and their dosage forms.
1 cl, 6 ex, 4 tbl, 2 dwg
SUBSTANCE: invention relates to veterinary. Method of increasing activity of natural killer-cells in animal includes introduction to animal of lipoic acid in amount from 10 mg to 1000 mg per day. Invention also relates to method of increasing immune response in animal by introduction to it of lipoic acid, as well as to composition, acceptable for increase of immune response or activity of natural killer-cells in animal, which includes: life-sustaining amount of nutrients and more than 50 ppm of lipoic acid, set for introduction of lipoic acid to animal, as well as to application of lipoic acid for obtaining medication for enhancing immune response and for increasing natural killer-cell activity in animal.
EFFECT: invention ensures increase of efficiency of natural killer-cell activity and immune response in animals.
28 cl, 1 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry. An immunomodulatory and antioxidant drug characterised by the fact that it represents Psephellus herb extract containing polyphenols in amount 8-10 mg/ml, polyacetylenes in amount 0.03-0.05 mg/ml, prepared in the relation raw material:extractant 1:5, during 7 days in absence of light, and the extractant is chosen from the group: 40% of alcohol, 5-75% of glycerine, 5-100% of honey and water. The drug can be presented as a capsule, a tablet, a powder, a pill, a dragee, granules, a sachet, gel, paste, syrup, an emulsion, a suspension, a solution, and a chewing gum. The drug can be applied for immune system correction in the patients untreatable with common medications.
EFFECT: production of the immunomodulatory and antioxidant drug.
2 cl, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention covers a water-soluble drug based on ionic silver and methylene blue compound, and also a method for preparing thereof. Said method implies synthesis when heating to 90-95°C by mixing the following components: methylene blue - silver chloride - ammonia in the molar ratio 1.06:1:58 to be cooled; a by-product is filtered, steamed in vacuum, washed with acetone and dried in vacuum at room temperature.
EFFECT: prepared drug meets the composition C16H18CI2N3SAg and exhibits antiviral and immunomodulatory action.
2 cl, 2 dwg, 3 tbl
SUBSTANCE: present invention relates to a kit for an immunogenic composition, and an immunogenic composition which contains a polynucleotide adjuvant composition together with an antigen (for example as a vaccine). The disclosed adjuvant compositions (versions) have special physical properties (for example molecular mass, concentration and pH), which meet requirements for a safe adjuvant for inducing intense immune response. The invention also relates to a method of preparing an immunogenic composition and using immunogenic adjuvant compositions, particularly for inducing immune response to an antigenic compound.
EFFECT: disclosed adjuvant compositions are safe and efficiently provide the desired immunogenic effect in humans.
25 cl, 2 dwg, 15 tbl, 16 ex
SUBSTANCE: invention relates to medicine and may be used to reduce human biological age. For this purpose preparation "Transfer-factor" is introduced to patient in dose of 1-3 capsules per day for 60-80 kg during 6 weeks.
EFFECT: reduced age-related changes in practically healthy people by recovery of potential of cellular growth of tissues.